Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:35:47.392Z.
Calculation as of: 2026-10-06T16:35:47.392Z.
Quote observation: 2026-10-06T16:34:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a5b8a39003d923715743cc0d1a2c59dcf36f227505f31b08d3d275f4059bcabd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Attovia Therapeutics, Inc.
Market Cap
$774.97M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$775.17M
Price/FCF Ratio
N/A
TTM Avg
2.47
3Y Avg
2.47
5Y Avg
6.40
Market Cap
$767.66M
Price/FCF Ratio
14.52
TTM Avg
13.25
3Y Avg
14.26
5Y Avg
22.71
Market Cap
$758.23M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$793.58M
Price/FCF Ratio
N/A
TTM Avg
424.04
3Y Avg
254.96
5Y Avg
216.79
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $774.97M | N/A | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $775.17M | N/A | 2.47 | 2.47 | 6.40 |
| Mesa Laboratories, Inc. (MLAB)vs › | $767.66M | 14.52 | 13.25 | 14.26 | 22.71 |
| Sana Biotechnology, Inc. (SANA)vs › | $783.39M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $788.50M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $758.23M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $795.49M | N/A | 60.32 | 60.32 | 60.32 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $793.58M | N/A | 424.04 | 254.96 | 216.79 |
| AdaptHealth Corp. (AHCO)vs › | $797.32M | 8.16 | 7.03 | 12.33 | 28.28 |
| InMode Ltd. (INMD)vs › | $805.92M | 9.22 | 9.91 | 9.93 | 15.12 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
